 Eileen Martin
Concepts (336)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 25 | 2018 | 105 | 9.150 |
Why?
| | HIV Infections | 52 | 2019 | 821 | 8.510 |
Why?
| | HIV Seropositivity | 24 | 2019 | 93 | 5.410 |
Why?
| | Neuropsychological Tests | 65 | 2019 | 1165 | 4.050 |
Why?
| | AIDS Dementia Complex | 15 | 2018 | 37 | 2.920 |
Why?
| | Psychomotor Performance | 18 | 2018 | 218 | 2.400 |
Why?
| | Cognition Disorders | 18 | 2018 | 1035 | 2.370 |
Why?
| | Memory Disorders | 9 | 2017 | 164 | 2.330 |
Why?
| | Decision Making | 9 | 2016 | 183 | 2.260 |
Why?
| | Cognition | 22 | 2019 | 907 | 2.190 |
Why?
| | Sex Characteristics | 5 | 2018 | 94 | 2.030 |
Why?
| | Adult | 87 | 2019 | 8754 | 1.950 |
Why?
| | Acquired Immunodeficiency Syndrome | 8 | 2017 | 100 | 1.890 |
Why?
| | Memory, Short-Term | 12 | 2019 | 80 | 1.870 |
Why?
| | Hepatitis C | 5 | 2015 | 57 | 1.770 |
Why?
| | Middle Aged | 75 | 2019 | 10097 | 1.680 |
Why?
| | Impulsive Behavior | 6 | 2013 | 19 | 1.680 |
Why?
| | Male | 84 | 2019 | 15601 | 1.490 |
Why?
| | Anti-HIV Agents | 10 | 2019 | 147 | 1.450 |
Why?
| | Reaction Time | 15 | 2018 | 107 | 1.450 |
Why?
| | Learning | 3 | 2013 | 85 | 1.410 |
Why?
| | Humans | 108 | 2019 | 26729 | 1.400 |
Why?
| | Attention | 11 | 2019 | 145 | 1.350 |
Why?
| | Drug Users | 3 | 2015 | 4 | 1.350 |
Why?
| | Risk-Taking | 4 | 2016 | 40 | 1.260 |
Why?
| | Cocaine-Related Disorders | 4 | 2017 | 16 | 1.250 |
Why?
| | HIV-1 | 15 | 2017 | 417 | 1.200 |
Why?
| | Antiretroviral Therapy, Highly Active | 10 | 2017 | 137 | 1.180 |
Why?
| | Female | 63 | 2019 | 15965 | 1.170 |
Why?
| | Gambling | 6 | 2013 | 8 | 1.020 |
Why?
| | Memory, Episodic | 2 | 2017 | 83 | 0.940 |
Why?
| | Spatial Learning | 1 | 2017 | 5 | 0.810 |
Why?
| | HIV Seronegativity | 6 | 2016 | 44 | 0.810 |
Why?
| | Mumps | 1 | 2017 | 1 | 0.810 |
Why?
| | Mumps Vaccine | 1 | 2017 | 1 | 0.810 |
Why?
| | Immunization Programs | 1 | 2017 | 2 | 0.810 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 8 | 0.810 |
Why?
| | Spatial Navigation | 1 | 2017 | 8 | 0.800 |
Why?
| | Homosexuality, Male | 5 | 2017 | 17 | 0.780 |
Why?
| | Mental Recall | 3 | 2016 | 66 | 0.750 |
Why?
| | Executive Function | 9 | 2019 | 87 | 0.750 |
Why?
| | Marijuana Abuse | 3 | 2014 | 5 | 0.710 |
Why?
| | Memory | 7 | 2019 | 313 | 0.710 |
Why?
| | Stress Disorders, Post-Traumatic | 3 | 2015 | 166 | 0.710 |
Why?
| | Depression | 7 | 2019 | 442 | 0.670 |
Why?
| | Delay Discounting | 1 | 2015 | 23 | 0.670 |
Why?
| | Verbal Learning | 6 | 2015 | 39 | 0.650 |
Why?
| | Brain | 9 | 2018 | 1266 | 0.640 |
Why?
| | Heroin Dependence | 5 | 2013 | 11 | 0.640 |
Why?
| | Hospitalization | 1 | 2017 | 285 | 0.630 |
Why?
| | Schizophrenic Psychology | 4 | 2002 | 27 | 0.620 |
Why?
| | Antisocial Personality Disorder | 3 | 2010 | 11 | 0.620 |
Why?
| | Sex Factors | 6 | 2019 | 471 | 0.590 |
Why?
| | Cohort Studies | 17 | 2019 | 1650 | 0.590 |
Why?
| | Suicide, Attempted | 1 | 2012 | 20 | 0.550 |
Why?
| | Amphetamine-Related Disorders | 2 | 2013 | 10 | 0.550 |
Why?
| | Adolescent | 12 | 2017 | 2397 | 0.540 |
Why?
| | Serial Learning | 1 | 2011 | 3 | 0.530 |
Why?
| | Analysis of Variance | 6 | 2011 | 366 | 0.510 |
Why?
| | Severity of Illness Index | 6 | 2019 | 1145 | 0.500 |
Why?
| | Unsafe Sex | 1 | 2010 | 7 | 0.490 |
Why?
| | Affective Symptoms | 1 | 2010 | 11 | 0.480 |
Why?
| | Motor Skills | 1 | 2010 | 47 | 0.480 |
Why?
| | Age Factors | 9 | 2019 | 829 | 0.460 |
Why?
| | Case-Control Studies | 9 | 2019 | 623 | 0.450 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 19 | 0.450 |
Why?
| | Alcoholism | 3 | 2014 | 72 | 0.440 |
Why?
| | Women | 1 | 2008 | 14 | 0.430 |
Why?
| | Professional Role | 1 | 2008 | 19 | 0.430 |
Why?
| | Neuropsychology | 1 | 2008 | 12 | 0.430 |
Why?
| | Career Choice | 1 | 2008 | 29 | 0.420 |
Why?
| | Auditory Perception | 3 | 2006 | 44 | 0.420 |
Why?
| | Marijuana Smoking | 2 | 2019 | 5 | 0.420 |
Why?
| | Diabetes Complications | 2 | 2018 | 56 | 0.420 |
Why?
| | Choice Behavior | 4 | 2013 | 57 | 0.400 |
Why?
| | Substance Abuse, Intravenous | 2 | 2005 | 12 | 0.390 |
Why?
| | Comorbidity | 4 | 2015 | 488 | 0.390 |
Why?
| | Predictive Value of Tests | 5 | 2013 | 586 | 0.380 |
Why?
| | Prefrontal Cortex | 4 | 2014 | 130 | 0.380 |
Why?
| | Schizophrenia | 3 | 2002 | 72 | 0.380 |
Why?
| | Young Adult | 9 | 2019 | 1937 | 0.370 |
Why?
| | Methamphetamine | 1 | 2007 | 44 | 0.360 |
Why?
| | Statistics as Topic | 3 | 2013 | 122 | 0.340 |
Why?
| | Exploratory Behavior | 1 | 2005 | 21 | 0.340 |
Why?
| | Problem Solving | 2 | 2002 | 46 | 0.330 |
Why?
| | Aged | 17 | 2019 | 8906 | 0.330 |
Why?
| | Psychometrics | 4 | 2013 | 248 | 0.330 |
Why?
| | Sexual Behavior | 1 | 2005 | 52 | 0.330 |
Why?
| | Risk Factors | 12 | 2018 | 2312 | 0.330 |
Why?
| | Depressive Disorder | 3 | 2014 | 213 | 0.330 |
Why?
| | Longitudinal Studies | 9 | 2018 | 1194 | 0.310 |
Why?
| | Magnetic Resonance Imaging | 8 | 2018 | 1124 | 0.300 |
Why?
| | Stress, Psychological | 2 | 2017 | 254 | 0.300 |
Why?
| | Psychiatric Status Rating Scales | 8 | 2008 | 379 | 0.300 |
Why?
| | Individuality | 2 | 2018 | 15 | 0.290 |
Why?
| | Concept Formation | 1 | 2002 | 12 | 0.290 |
Why?
| | Visual Perception | 2 | 2016 | 65 | 0.290 |
Why?
| | Prospective Studies | 11 | 2018 | 1590 | 0.280 |
Why?
| | Social Adjustment | 1 | 2002 | 32 | 0.280 |
Why?
| | Psychotic Disorders | 1 | 2002 | 49 | 0.280 |
Why?
| | Personality | 2 | 2013 | 56 | 0.260 |
Why?
| | Self Report | 3 | 2018 | 179 | 0.260 |
Why?
| | Educational Status | 5 | 2015 | 246 | 0.260 |
Why?
| | Intelligence Tests | 2 | 2011 | 16 | 0.260 |
Why?
| | Cues | 2 | 2000 | 74 | 0.250 |
Why?
| | Bipolar Disorder | 2 | 2002 | 112 | 0.240 |
Why?
| | White Matter | 2 | 2018 | 95 | 0.240 |
Why?
| | Central Nervous System Stimulants | 3 | 2017 | 54 | 0.240 |
Why?
| | Thinking | 1 | 2000 | 20 | 0.240 |
Why?
| | Benzoxazines | 1 | 2019 | 8 | 0.230 |
Why?
| | Drug Substitution | 1 | 2019 | 3 | 0.230 |
Why?
| | Statistics, Nonparametric | 2 | 2016 | 159 | 0.230 |
Why?
| | Obesity, Abdominal | 1 | 2019 | 20 | 0.230 |
Why?
| | Ethnic Groups | 5 | 2019 | 143 | 0.210 |
Why?
| | Demography | 3 | 2014 | 79 | 0.210 |
Why?
| | Energy Metabolism | 1 | 2018 | 72 | 0.210 |
Why?
| | Incidence | 2 | 2018 | 727 | 0.200 |
Why?
| | Disease Progression | 3 | 2015 | 759 | 0.200 |
Why?
| | Spain | 1 | 2017 | 20 | 0.200 |
Why?
| | Crack Cocaine | 2 | 2014 | 4 | 0.200 |
Why?
| | Chicago | 3 | 2013 | 808 | 0.200 |
Why?
| | Vaccination | 1 | 2017 | 32 | 0.200 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2010 | 46 | 0.200 |
Why?
| | Psychological Tests | 3 | 2007 | 65 | 0.200 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 19 | 0.200 |
Why?
| | Personality Tests | 1 | 2016 | 8 | 0.190 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 79 | 0.190 |
Why?
| | Disease Outbreaks | 1 | 2017 | 83 | 0.190 |
Why?
| | United States | 8 | 2019 | 2104 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2017 | 88 | 0.180 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 153 | 0.180 |
Why?
| | Aged, 80 and over | 8 | 2019 | 4537 | 0.180 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 303 | 0.180 |
Why?
| | Personality Inventory | 1 | 2016 | 82 | 0.180 |
Why?
| | Smoking | 1 | 2017 | 170 | 0.180 |
Why?
| | Aging | 3 | 2017 | 1300 | 0.180 |
Why?
| | Obesity | 2 | 2019 | 287 | 0.170 |
Why?
| | Cerebral Cortex | 2 | 2016 | 174 | 0.170 |
Why?
| | Adiponectin | 1 | 2015 | 13 | 0.170 |
Why?
| | Infant | 1 | 2017 | 600 | 0.170 |
Why?
| | Catechol O-Methyltransferase | 1 | 2014 | 5 | 0.170 |
Why?
| | Hippocampus | 1 | 2017 | 249 | 0.170 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 178 | 0.170 |
Why?
| | Time Factors | 4 | 2013 | 1736 | 0.160 |
Why?
| | Child, Preschool | 1 | 2017 | 752 | 0.160 |
Why?
| | CD4 Lymphocyte Count | 4 | 2017 | 149 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2015 | 114 | 0.160 |
Why?
| | RNA, Viral | 1 | 2015 | 165 | 0.160 |
Why?
| | Gyrus Cinguli | 1 | 2014 | 22 | 0.160 |
Why?
| | Quality of Life | 1 | 2019 | 534 | 0.160 |
Why?
| | Cross-Sectional Studies | 4 | 2017 | 791 | 0.160 |
Why?
| | Prevalence | 4 | 2017 | 496 | 0.160 |
Why?
| | Drug Therapy, Combination | 3 | 2017 | 251 | 0.150 |
Why?
| | Menopause | 1 | 2014 | 97 | 0.150 |
Why?
| | Zidovudine | 3 | 1999 | 39 | 0.150 |
Why?
| | Apolipoprotein E4 | 1 | 2014 | 178 | 0.150 |
Why?
| | Anxiety | 2 | 2010 | 136 | 0.140 |
Why?
| | Child | 1 | 2017 | 1393 | 0.140 |
Why?
| | Genotype | 4 | 2014 | 407 | 0.140 |
Why?
| | Hospitals, Veterans | 1 | 2012 | 6 | 0.140 |
Why?
| | Patient Selection | 1 | 2014 | 235 | 0.140 |
Why?
| | Association Learning | 1 | 2012 | 14 | 0.140 |
Why?
| | Regression Analysis | 4 | 2016 | 305 | 0.130 |
Why?
| | Follow-Up Studies | 6 | 2015 | 1872 | 0.130 |
Why?
| | Orientation | 1 | 1992 | 32 | 0.130 |
Why?
| | Pattern Recognition, Visual | 1 | 1992 | 36 | 0.130 |
Why?
| | Viral Load | 3 | 2017 | 194 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 154 | 0.130 |
Why?
| | Socioeconomic Factors | 2 | 2010 | 321 | 0.130 |
Why?
| | Blood Platelets | 1 | 2011 | 51 | 0.130 |
Why?
| | Caudate Nucleus | 1 | 2011 | 19 | 0.130 |
Why?
| | Bethanechol Compounds | 2 | 1988 | 6 | 0.130 |
Why?
| | Reading | 1 | 2011 | 35 | 0.130 |
Why?
| | Putamen | 1 | 2011 | 23 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 254 | 0.130 |
Why?
| | Psychomotor Disorders | 1 | 2010 | 11 | 0.130 |
Why?
| | Stroop Test | 1 | 2010 | 3 | 0.120 |
Why?
| | Games, Experimental | 1 | 2009 | 8 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 93 | 0.120 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2011 | 204 | 0.120 |
Why?
| | Stroke | 1 | 2013 | 310 | 0.120 |
Why?
| | Alzheimer Disease | 4 | 1992 | 1448 | 0.110 |
Why?
| | Atrophy | 3 | 2016 | 99 | 0.110 |
Why?
| | Dementia | 1 | 2014 | 451 | 0.110 |
Why?
| | Social Values | 1 | 2008 | 11 | 0.110 |
Why?
| | Frontal Lobe | 2 | 1995 | 84 | 0.110 |
Why?
| | Antipsychotic Agents | 2 | 2002 | 90 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2015 | 373 | 0.100 |
Why?
| | Infusion Pumps | 1 | 1988 | 15 | 0.100 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 5 | 1996 | 77 | 0.100 |
Why?
| | Reproducibility of Results | 4 | 2012 | 778 | 0.100 |
Why?
| | HIV | 2 | 2011 | 79 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2017 | 2780 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2008 | 135 | 0.100 |
Why?
| | Leadership | 1 | 2008 | 81 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2007 | 104 | 0.100 |
Why?
| | Mental Health | 2 | 2019 | 81 | 0.090 |
Why?
| | Societies, Medical | 1 | 2008 | 183 | 0.090 |
Why?
| | Bisexuality | 2 | 2017 | 9 | 0.090 |
Why?
| | Depressive Disorder, Major | 2 | 2003 | 100 | 0.090 |
Why?
| | Activities of Daily Living | 3 | 2002 | 418 | 0.080 |
Why?
| | Homosexuality | 2 | 2015 | 9 | 0.080 |
Why?
| | Substance Abuse Detection | 1 | 2004 | 5 | 0.080 |
Why?
| | Research | 1 | 2005 | 58 | 0.080 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 1995 | 11 | 0.080 |
Why?
| | Alleles | 2 | 2014 | 198 | 0.080 |
Why?
| | Alcohol Drinking | 1 | 2004 | 64 | 0.080 |
Why?
| | Probability | 1 | 2004 | 96 | 0.080 |
Why?
| | Organ Size | 2 | 2016 | 116 | 0.080 |
Why?
| | Electroconvulsive Therapy | 1 | 2003 | 17 | 0.080 |
Why?
| | Gene Expression | 2 | 2014 | 256 | 0.080 |
Why?
| | Principal Component Analysis | 2 | 2013 | 23 | 0.070 |
Why?
| | Schizotypal Personality Disorder | 1 | 1982 | 1 | 0.070 |
Why?
| | Electric Stimulation | 1 | 2003 | 86 | 0.070 |
Why?
| | Rehabilitation, Vocational | 1 | 2002 | 2 | 0.070 |
Why?
| | Delusions | 1 | 2002 | 13 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2002 | 82 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2002 | 136 | 0.070 |
Why?
| | Communication | 1 | 1982 | 98 | 0.070 |
Why?
| | Hallucinations | 1 | 2002 | 93 | 0.070 |
Why?
| | Patient Discharge | 1 | 2002 | 124 | 0.060 |
Why?
| | Reference Values | 4 | 2012 | 249 | 0.060 |
Why?
| | Cardiovascular Diseases | 2 | 2016 | 311 | 0.060 |
Why?
| | Chronic Disease | 1 | 2002 | 485 | 0.060 |
Why?
| | Zalcitabine | 1 | 1999 | 2 | 0.060 |
Why?
| | Didanosine | 1 | 1999 | 7 | 0.060 |
Why?
| | CD4-CD8 Ratio | 1 | 1999 | 15 | 0.060 |
Why?
| | Waist Circumference | 1 | 2019 | 30 | 0.060 |
Why?
| | Cities | 1 | 2018 | 14 | 0.050 |
Why?
| | Parietal Lobe | 2 | 1995 | 20 | 0.050 |
Why?
| | Posture | 1 | 1998 | 84 | 0.050 |
Why?
| | Movement | 1 | 2019 | 156 | 0.050 |
Why?
| | Dominance, Cerebral | 2 | 1995 | 24 | 0.050 |
Why?
| | Pilot Projects | 1 | 1999 | 389 | 0.050 |
Why?
| | Cell Count | 1 | 2017 | 114 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2017 | 53 | 0.050 |
Why?
| | Systems Biology | 1 | 2017 | 9 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 27 | 0.050 |
Why?
| | Postoperative Complications | 2 | 1995 | 978 | 0.050 |
Why?
| | Radiography | 2 | 2011 | 699 | 0.050 |
Why?
| | Body Mass Index | 1 | 2019 | 382 | 0.050 |
Why?
| | Dopamine | 2 | 2014 | 154 | 0.050 |
Why?
| | Medication Adherence | 1 | 2017 | 77 | 0.050 |
Why?
| | Gray Matter | 1 | 2016 | 45 | 0.050 |
Why?
| | Language | 1 | 1996 | 62 | 0.040 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 34 | 0.040 |
Why?
| | Cerebrovascular Circulation | 2 | 1995 | 52 | 0.040 |
Why?
| | Leptin | 1 | 2015 | 19 | 0.040 |
Why?
| | Language Disorders | 1 | 1995 | 12 | 0.040 |
Why?
| | Serotyping | 1 | 2014 | 12 | 0.040 |
Why?
| | Methylphenidate | 1 | 1995 | 8 | 0.040 |
Why?
| | Hematoma | 1 | 1995 | 18 | 0.040 |
Why?
| | Aphasia, Broca | 1 | 1994 | 2 | 0.040 |
Why?
| | Anomia | 1 | 1994 | 3 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2017 | 760 | 0.040 |
Why?
| | Chemokine CCL3 | 1 | 2014 | 12 | 0.040 |
Why?
| | Models, Statistical | 1 | 2015 | 135 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2015 | 128 | 0.040 |
Why?
| | Temporal Lobe | 1 | 1995 | 100 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2015 | 81 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 25 | 0.040 |
Why?
| | Motivation | 1 | 1995 | 91 | 0.040 |
Why?
| | Continental Population Groups | 1 | 2014 | 100 | 0.040 |
Why?
| | African Americans | 2 | 2013 | 633 | 0.040 |
Why?
| | Survival Analysis | 1 | 2014 | 372 | 0.040 |
Why?
| | Models, Neurological | 1 | 1994 | 34 | 0.040 |
Why?
| | Heroin | 1 | 2013 | 3 | 0.040 |
Why?
| | Avoidance Learning | 2 | 2010 | 8 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1995 | 143 | 0.040 |
Why?
| | Color Perception | 1 | 1992 | 7 | 0.040 |
Why?
| | Cannabis | 1 | 2012 | 5 | 0.040 |
Why?
| | Models, Genetic | 1 | 2012 | 36 | 0.040 |
Why?
| | Quality Control | 1 | 2012 | 47 | 0.030 |
Why?
| | Haplotypes | 1 | 2012 | 60 | 0.030 |
Why?
| | Platelet Count | 1 | 2011 | 22 | 0.030 |
Why?
| | Bethanechol | 2 | 1988 | 5 | 0.030 |
Why?
| | Health Surveys | 1 | 2011 | 94 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2010 | 6 | 0.030 |
Why?
| | Phenotype | 1 | 2012 | 331 | 0.030 |
Why?
| | Neuroimaging | 1 | 2011 | 87 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 65 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 55 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 336 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2011 | 92 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2011 | 225 | 0.030 |
Why?
| | Ultrasonography | 1 | 2011 | 186 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 204 | 0.030 |
Why?
| | Animals | 2 | 2018 | 4851 | 0.030 |
Why?
| | Verbal Behavior | 2 | 1994 | 23 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 426 | 0.030 |
Why?
| | Algorithms | 1 | 2011 | 385 | 0.030 |
Why?
| | Prognosis | 1 | 2011 | 920 | 0.030 |
Why?
| | Behavior | 1 | 1988 | 30 | 0.030 |
Why?
| | Anisotropy | 1 | 2008 | 49 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 1988 | 123 | 0.030 |
Why?
| | Affect | 1 | 2008 | 67 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2007 | 88 | 0.020 |
Why?
| | Mental Processes | 1 | 2006 | 17 | 0.020 |
Why?
| | Reference Standards | 1 | 2006 | 32 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1988 | 510 | 0.020 |
Why?
| | Biopsy | 1 | 1987 | 267 | 0.020 |
Why?
| | Intelligence | 1 | 2005 | 27 | 0.020 |
Why?
| | Counseling | 1 | 1986 | 62 | 0.020 |
Why?
| | African Continental Ancestry Group | 1 | 2006 | 157 | 0.020 |
Why?
| | Regional Blood Flow | 2 | 1995 | 18 | 0.020 |
Why?
| | Behavior Therapy | 1 | 1986 | 77 | 0.020 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2003 | 15 | 0.020 |
Why?
| | Aversive Therapy | 1 | 1983 | 1 | 0.020 |
Why?
| | Hypophysectomy | 1 | 1983 | 3 | 0.020 |
Why?
| | Schizophrenic Language | 1 | 1982 | 1 | 0.020 |
Why?
| | Parkinson Disease | 1 | 1992 | 1026 | 0.020 |
Why?
| | Morphine | 1 | 1983 | 61 | 0.020 |
Why?
| | European Continental Ancestry Group | 1 | 2006 | 528 | 0.020 |
Why?
| | Motor Activity | 1 | 2003 | 375 | 0.010 |
Why?
| | Reflex | 1 | 1998 | 4 | 0.010 |
Why?
| | Electromyography | 1 | 1998 | 88 | 0.010 |
Why?
| | Leg | 1 | 1998 | 46 | 0.010 |
Why?
| | Rotation | 1 | 1998 | 144 | 0.010 |
Why?
| | Forecasting | 1 | 1998 | 128 | 0.010 |
Why?
| | Bolivia | 1 | 1995 | 3 | 0.010 |
Why?
| | Amobarbital | 1 | 1995 | 3 | 0.010 |
Why?
| | Epilepsy, Generalized | 1 | 1995 | 8 | 0.010 |
Why?
| | Arteriovenous Malformations | 1 | 1995 | 3 | 0.010 |
Why?
| | Epilepsy | 1 | 1996 | 100 | 0.010 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 1994 | 1 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 1994 | 14 | 0.010 |
Why?
| | Postoperative Period | 1 | 1995 | 213 | 0.010 |
Why?
| | Social Behavior | 1 | 1995 | 103 | 0.010 |
Why?
| | Neural Pathways | 1 | 1994 | 82 | 0.010 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 26 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1988 | 515 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 1988 | 370 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1995 | 3364 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1983 | 12 | 0.000 |
Why?
| | Conditioning, Classical | 1 | 1983 | 7 | 0.000 |
Why?
| | Rats | 1 | 1983 | 915 | 0.000 |
Why?
|
|
Martin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|